CervoMed SEC Filings

CervoMed Inc. reported an insider equity award linked to its CEO and President, John J. Alam. The Form 4 shows a grant of stock options covering 8,150 shares of common stock at an exercise price of $2.91 per share, held indirectly through his spouse.

The options were granted to Dr. Sylvie Gregoire, a non-employee director and spouse of the reporting person. The filing states that Alam disclaims beneficial ownership of these securities. The underlying shares vest monthly over one year in substantially equal 1/12 increments, beginning on June 30, 2026, subject to Dr. Gregoire’s continued service.

CervoMed Inc. entered into a securities purchase agreement for a private placement of 3,360,377 units, each consisting of common stock or a pre-funded warrant plus Series B and Series C warrants, at $3.14 or $3.139 per unit, for anticipated gross proceeds of about $10.5 million.

The financing, which includes substantial participation from company insiders and institutional healthcare investors, could generate up to an additional $21.7 million if the Series B and Series C warrants are fully exercised for cash. CervoMed plans to use the funds to advance its lead drug neflamapimod and general corporate needs, and expects its cash runway, together with existing cash, to extend into the second quarter of 2027 while it pursues a strategic partnership to move neflamapimod into Phase 3 for dementia with Lewy bodies.

CervoMed Inc. held its 2026 Annual Meeting of Stockholders on June 8, 2026. Stockholders of record on April 17, 2026 could vote, with 9,258,719 shares of common stock outstanding as of that date.

Holders of 6,218,593 shares, or about 67.2% of shares outstanding, were present virtually or by proxy, so a quorum was achieved. All eight director nominees received the requisite plurality of votes and were elected. Three additional proposals, each requiring a majority of votes present and entitled to vote, were approved, including Proposal No. 2 with 6,092,751 votes for and Proposal No. 3 and Proposal No. 4 with more votes for than against.

CervoMed Inc. reported first-quarter 2026 results, including cash, cash equivalents and marketable securities of $12.9 million as of March 31, 2026. This compares to $20.9 million as of December 31, 2025, and the company expects this cash to fund operations into the third quarter of 2026.

For the quarter, CervoMed recorded no grant revenue versus approximately $1.9 million a year earlier, reflecting completion of its RewinD-LB trial and the end of related grant funding. Research and development expenses were about $5.1 million, up from $4.8 million, while general and administrative expenses rose to roughly $3.0 million from $2.4 million.

Net loss widened to approximately $8.0 million from $4.9 million, driven mainly by the grant revenue decline and higher operating costs. On the clinical side, the company highlighted extensive neflamapimod data in dementia with Lewy bodies and alignment with regulators on the final design of a planned Phase 3 trial, which it aims to start in the second half of 2026, subject to financing.

CervoMed Inc. reported a net loss of $7.96M for the quarter ended March 31, 2026, wider than $4.89M a year earlier, as grant revenue from its NIA award dropped to zero and operating expenses rose.

Research and development spending increased to $5.14M, driven by CMC work on neflamapimod and expansion into frontotemporal disorders and recovery-after-stroke programs, while general and administrative costs rose to $2.98M on higher headcount and professional fees.

CervoMed ended the quarter with $12.9M in cash, cash equivalents and marketable securities and an accumulated deficit of $105.7M. Management states there is substantial doubt about the company’s ability to continue as a going concern, as current resources are not expected to fund operations for 12 months without new financing.

CervoMed Inc reports that Morgan Stanley entities hold an 8.0% beneficial ownership stake. The filing attributes shared voting power of 736,624 shares and shared dispositive power of 739,736 shares to Morgan Stanley reporting units. The filing is a joint Schedule 13G/A amendment signed by authorized Morgan Stanley representatives.

CervoMed Inc. is asking stockholders to vote at its virtual 2026 Annual Meeting on June 8, 2026. Items include electing eight directors, ratifying RSM US LLP as auditor for 2026, an advisory vote on 2025 executive pay, and approving Amendment No. 1 to the 2025 Equity Incentive Plan.

Stockholders of record as of April 17, 2026, when 9,258,719 common shares were outstanding, may attend and vote online. The Board, which includes a majority of independent directors, recommends voting in favor of all four proposals. The proxy also outlines governance practices, committee structures, and detailed executive and director compensation.

CervoMed Inc. reported new brain imaging data from its Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), presented at the 2026 AAN Annual Meeting. The analyses showed neflamapimod increased basal forebrain volume and functional connectivity compared with placebo, suggesting disease-related brain changes might be partly reversible.

The company highlights alignment with preclinical work and prior blood biomarker results, supporting the idea that neflamapimod may act on underlying DLB biology rather than just symptoms. CervoMed plans a global, pivotal Phase 3 DLB trial in the second half of 2026, subject to securing sufficient financing.